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Development of live attenuated 
Enterovirus 71 vaccine strains that 
confer protection against lethal 
challenge in mice
pinn tsin Isabel Yee1, soon Hao tan2, Kien Chai Ong2, Kuan onn tan3, Kum Thong Wong4, 
Sharifah Syed Hassan5 & Chit Laa Poh1
Besides causing mild hand, foot and mouth infections, Enterovirus A71 (EV-A71) is associated with 
neurological complications and fatality. With concerns about rising EV-A71 virulence, there is an 
urgency for more effective vaccines. The live attenuated vaccine (LAV) is a more valuable vaccine as it 
can elicit both humoral and cellular immune responses. A miRNA-based vaccine strain (pIY) carrying 
let-7a and miR-124a target genes in the EV-A71 genome which has a partial deletion in the 5′NTR 
(∆11 bp) and G64R mutation (3Dp°l) was designed. The viral RNA copy number and viral titers of the pIY 
strain were significantly lower in SHSY-5Y cells that expressed both let-7a and miR-124a. Inhibition of 
the cognate miRNAs expressed in RD and SHSY-5Y cells demonstrated de-repression of viral mRNA 
translation. A previously constructed multiply mutated strain, MMS and the pIY vaccine strain were 
assessed in their ability to protect 4-week old mice from hind limb paralysis. The MMS showed higher 
amounts of IFN-γ ex vivo than the pIY vaccine strain. There was absence of EV-A71 antigen in the 
skeletal muscles and spinal cord micrographs of mice vaccinated with the MMS and pIY strains. The 
MMS and pIY strains are promising LAV candidates developed against severe EV-A71 infections.
The hand, foot, and mouth disease (HFMD) is generally manifested as a mild illness but neurological compli-
cations such as encephalomyelitis, acute flaccid paralysis and aseptic meningitis have occurred in infants and 
young children below 6 years of age1. Enteroviruses such as Enterovirus 71 (EV-A71), Coxsackievirus type A16 
(CV-A16) and other enteroviruses causing HFMD have led to over 7 million infections, including 2457 fatalities 
in China from 2008 to 20122. Most HFMD infections that led to fatality were due to the EV-A71 virus3. Since 
1997, countries such as Taiwan, Malaysia, Singapore and Vietnam have experienced cyclical epidemics which 
occurred every 2 or 3 years. EV-A71 was first isolated as the etiological agent of HFMD from a young child in 
California, United States in 19694. The virus is a member of the human Enterovirus Species A group within the 
family Picornaviridae5.
With rising concern about the virulence of EV-A71, there is an urgent need for a vaccine against EV-A71 to be 
produced that is approved by FDA. China’s FDA has issued drug certificates and production licenses for the inac-
tivated vaccine (IV) from 3 companies namely, Sinovac, Vigoo and CAMS6. An IV was found to elicit weak T cell 
responses because there were decreased amounts of antigen in the IV to sustain prolonged antibody responses7. 
The efficacy of the IVs against EV-A71 is predominantly dependent on antibody-mediated protection. The surface 
proteins of viruses will continuously undergo genetic changes through evolution of the genome and this could 
affect effective neutralization of newly evolved strains by antibodies elicited by the current vaccine strain8. Since 
IVs do not elicit long-term immune memory, it would also require several booster vaccinations after adminis-
tration. The live attenuated vaccine (LAV) may serve as a more effective vaccine as it can elicit both humoral and 
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cellular immune responses. Recent studies indicated that cellular and not humoral immunity determines the 
clinical outcome of EV-A71 infections as there was no difference in NtAb titers between mild and fatal HFMD 
cases9. It was discovered that approximately 93% of T cell responses were induced by antigens from the structural 
VP2 region as compared with antigens from VP1, VP3 and VP4 after in vitro expansion. These cellular responses 
were predominantly from the IFN-γ-CD4+ T cells and not from the CD8+ T cells10.
MicroRNAs (miRNAs) are 20–24 nucleotides long, non-coding RNAs that can prevent translation of messen-
ger RNA (mRNA)11. Insertion of miRNA into a viral genome has been shown to control viral tropism. The virus 
expressing the corresponding miRNA would not be able to replicate in cells that carried the specific miRNA and 
would thereby display an attenuated phenotype12. The human genome has more than 1000 different miRNAs that 
are tissue specific and can function as post-transcriptional regulators, capable of repressing hundreds of genes 
and regulating many cellular processes13,14. An ideal attenuated virus vaccine should be one that does not replicate 
in tissues to cause disease and yet at the same time, replicate sufficiently in other tissues to elicit a long-lasting 
immune reaction15. Using the miRNA-based approach, Barnes et al.12 inserted miRNA coding sites for let-7a or 
miR-124a into the poliovirus genome and showed that there was restricted viral replication in the murine central 
nervous system (CNS). Although the degree of attenuation of neuro-virulence exceeded 5 orders of magnitude, 
these engineered miRNA viruses were still able to replicate in non-neuronal tissues and elicited high neutralizing 
antibody (NtAb) titers. Thus, the viruses encoding miRNAs could stimulate a strong protective immunity without 
the adverse risk of causing paralysis in the host.
Previously, we had identified significant genetic determinants of virulence in the EV-A71 virus (sub-genotype 
B4 virus; 5865/Sin/000009) and the information was used to construct the multiply mutated EV-A71 strain, 
MMS which carried a substitution of nucleotide U to C (U700C) at the 5′-NTR, replacement of amino acid (aa) 
E to G at VP1-145 (E145G), 3 amino acid replacements at positions 98, 242, and 244 of VP1 and replacement of 
an amino acid at position 64 of the 3Dp°l (G64R) in the mutant that had a partial deletion (∆11 bp in 5′-NTR)16. 
In this study, we constructed the EV-A71 miRNA-based vaccine strain (pIY) to carry let-7a and miR-124a target 
genes. As cellular miRNAs have such diverse tissue-specific distributions, the attenuation effects of the pIY vac-
cine strain carrying both miRNAs let-7a and miR-124a were assessed to demonstrate that the vaccine strain could 
indeed decrease viral pathogenesis in different cell types. This attenuation could be due to the binding between 
the endogenous cellular miRNA and the viral miRNA target sequences, inducing miRNA cleavage and causing 
significant reduction of viral replications. We evaluated the ability of the MMS and the miRNA strain (pIY) to act 
as vaccines in protecting mice against a mouse adapted virus strain (MAV) in challenge studies17.
Results
Construction of the recombinant pIY vaccine strain carrying microRNAs. Two microRNA target 
genes, let-7a and miR-124a, were inserted into the EV-A71 mutant strain that carried a partial deletion (nt. 475–
485 in the 5′-NTR) and a substitution of nucleotide at position 6129 (nt G to nt C) at the 3Dp°l region (G64R). 
The miRNA target sequence for let-7a was inserted at the 3′end of the 5′-NTR in the EV-A71 genome while the 
target sequence for miR-124a was located between the structural (VP1) and non-structural (2 A) genes within the 
coding region (Fig. 1a). Recombinant EV-A71 genomes carrying the miRNA let-7a, miR-124a target genes and 
recombinant EV-A71 genomes containing scrambled miRNA genes were generated. The recombinant plasmid 
containing the correct target sequences (pTOPO-miRNA7124) and recombinant plasmid carrying scrambled 
sequences were confirmed by sequencing (Fig. 1b). The recombinant plasmid pTOPO-miRNA7124 that carried 
the let-7a and miR-124a target genes, and the G64R mutation in the EV-A71 genome with 11 bp deletion in the 
5′-NTR was transformed into a competent E.coli strain. After in vitro transcription, infectious viral RNAs that 
were produced were transfected into RD cells with Lipofectamine 2000. The recombinant viruses released from 
RD cells upon lysis was designated as the pIY miRNA vaccine strain.
Quantification of the levels of the viral RNA copy number in RD and SHSY-5Y cells before and after infection 
(24 h) with the pIY strain was determined. There was a significant 3-fold decrease (P = 0.0082) in let-7a miRNA 
relative expression levels in RD cells when comparing pre- and post-infection (24 h) with the pIY strain. This is 
expected as the cognate let-7a in RD cells would bind to the complementary let-7a target sequence in the pIY strain 
and thereby, reduce the expression levels of let-7a. For SHSY-5Y cells, the let-7a expression levels (P = 0.0012) 
decreased after 24 h post-infection with the pIY vaccine strain. There was also a significant 4-fold reduction 
(P = 0.0064) in miR-124a expression levels when comparing the pre- and post-infection stages of pIY strain in 
SHSY-5Y cells (24 h). This could be attributed to the abundance of neuronal miR-124a in SHSY-5Y cells (Fig. 1c).
Quantitation of viral titer in different cell lines. Replication of the pIY miRNA vaccine strain carrying 
the two microRNAs in RD, SHYS-5Y and NTERA-2 cells were evaluated by plaque assays at a MOI of 0.1. The 
RD cells infected with the pIY strain exhibited significant reduction of viral titer to 2.4 × 104 PFU/ml in RD cells 
(P = 0.0443) (Fig. 2ai). The EV-A71 wild-type (WT) virus infection in RD cells led to as high as 8.0 × 107 PFU/
ml (Fig. 2aii). As expected, the recombinant virus carrying the pIY scrambled sequences (pIY-scr) in infected 
RD cells generated viruses with a PFU/ml of 4.8 × 107, this was similar to that observed for the wild type EV-A71 
(Fig. 2aiii). The SHSY-5Y cells infected with the pIY strain exhibited significant reduction of viral titer to 3.5 × 104 
PFU/ml in SHSY-5Y cells (P = 0.0325) (Fig. 2aiv). The EV-A71 WT virus infection in SHSY-5Y cells reached as 
high as 5.0 × 107 PFU/ml in SH-SY5Y cells (Fig. 2av). The virus carrying the pIY scrambled sequences (pIY-scr) 
in infected SH-SY5Y cells generated viruses with a viral titer of 3.4 × 107 PFU/ml (Fig. 2avi).
However, infection by recombinant pIY in NTERA-2 cells exhibited no significant (P = 0.5029) reduction of 
viral titer, with a viral count of 6.5 × 107 PFU/ml (Fig. 2avii). This is similar to that observed for the WT virus 
which generated 9.8 × 107 PFU/ml in NTERA-2 cells (Fig. 2aviii). The pIY-scr-infected NTERA-2 cells had viral 
titer of 8.2 × 107 PFU/ml, a value which is similar to the viral titer achieved by infection of the wild type EV-A71 
(Fig. 2aix). As NTERA-2 cells did not express endogenous let-7a and miR-124a, there was no cognate miRNAs 
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binding to the complementary target genes on the pIY vaccine strain to reduce miRNA expression and subse-
quent generation of infectious viral particles12. There was a significant 3-log reduction of viral titer (P = 0.0325) 
when the PFU/ml values were compared between the pIY-infected SHYSY-5Y cells (3.6 × 104 log10 PFU/ml) and 
the EV-A71 wild type-infected SHYSY-5Y cells (5.0 × 107 log10 PFU/ml) (Fig. 2b). As there was reduction in viral 
growth, this is indicative that the plaque forming capability of the pIY vaccine strain was significantly reduced 
in both RD and SHSY-5Y cells due to the presence of their respective cognate miRNAs. This signifies that there 
would be weaker viremia due to a reduction in viral copy number as higher viral load is known to correlate with 
higher virulence.
Viral RNA copy determination in different cell lines. When overnight grown RD/SHSY-5Y/NTERA-2 
cells (1.5 × 105 cells/well in a 24-well plate) were infected with the pIY vaccine strain, pIY-scr and WT, the growth 
kinetics was measured after 0, 2, 4, 6, 8, 10, 12, and 24 h post-infection. The pIY strain from infected NTERA-2 
cells yielded significantly higher RNA copy number than the pIY strain from infected SHYSY-5Y or RD cells at all 
hpi. By 24 hpi, the pIY strain from infected SHYSY-5Y cells had 1.7-log10 lesser RNA copy number (5.8 ± 0.2 log10 
RNA copies/ml), as compared to the pIY recovered from infected NTERA-2 cells (9.9 ± 0.1 log10 RNA copies/
ml) (P = 0.0042). Similarly, the RNA copy number of pIY recovered from RD cells (6.0 ± 0.2 log10 RNA copies/
ml) was 1.5-log10 lesser than the pIY recovered from infected NTERA-2 cells (9.9 ± 0.1 log10 RNA copies/ml) 
(P = 0.0072) (Fig. 3a).
By 24-hour post infection, the difference between viral RNA copy numbers of NTERA-2 cells when compared 
with RD and SHSY-5Y cells was significant, showing attenuation due to presence of let-7a in RD cells and both 
let-7a and miR-124a in SHSY-5Y cells. The pIY strain following infection in RD cells produced 6.0 ± 0.2 log10 
Figure 1. Engineering EV-A71 virus sub-genotype B4 strain 41 to carry 2 miRNA target sequences and miRNA 
relative expression levels of let-7a and miR-124a in cell lines. (a) Target sequences complementary to the two 
miRNAs (let-7a and miR124a) were inserted into 2 locations within the EV-A71 genome. The miRNA target 
sequence for let-7a was inserted at the 3′end of the 5′-NTR. The target sequence for miR-124a was located 
between the VP1 structural and 2A non-structural region. (b) Perfect sequence complementarity between 
the target sequence and miRNA inserted into the EV-A71 genome. Scrambled target sequences referred to 
imperfect complementarity between the scrambled target sequence and miRNA inserted into the EV-A71 
genome. (c) Relative expression levels of let-7a and miR-124a in RD and SHSY-5Y cells after pIY vaccine strain 
pre-infection and 24 h post-infection. The relative expression was calculated with reference to control samples 
comprising cognate endogenous miRNA levels in the respective cell lines before pIY infection. Error bars 
indicate the standard deviation of the mean; P-values between the different groups with the one-way ANOVA. 
*P < 0.05, **P < 0.01.
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RNA copies/ml and this is a significant 2-log decrease (P = 0.0003) in RNA copy number than that produced 
by the WT positive control (10.0 ± 0.2 log10 RNA copies/ml). Similarly, 2-log decrease of RNA copy number 
(5.8 ± 0.2 log10 RNA copies/ml) (P = 0.001), was observed in pIY-infected SHSY-5Y cells, when compared to the 
WT infected SHSY-5Y cells (9.2 ± 0.1 log10 RNA copies/ml). The pIY-scr strain produced 9.5 ± 0.2 log10 RNA 
copies/ml when RD cells were infected with pIY-scr strain and the copy number was close to that observed 
for the WT infected RD cells (10.0 ± 0.2 log10 RNA copies/ml). This was also observed for the pIY-scr infected 
SHSY-5Y cells that produced similar amount of viral RNA copy number (9.7 ± 0.4 log10 RNA copies/ml) as that 
of the pIY-scr infected RD cells. Whereas for the NTERA-2 cells that did not express either of the miRNAs, the 
log10 viral copy number of the pIY strain remained high at a level which was quite comparable to the viral copies 
produced by the pIY-scr strain infected NTERA-2 cells (10.3 ± 0.1 log10 RNA copies/ml) (P = 0.4182) and the WT 
(10.7 ± 0.1 log10 RNA copies/ml) (Fig. 3b). In contrast, the negative control cell cultures without virus infection 
showed an absence of RNA copy number.
To confirm that the reduction in RNA copy number of the pIY strain in RD and SHSY-5Y cells were due to the 
presence of the miRNA target genes incorporated in the genome, the expression of the pIY strain in the presence 
of the respective chemically modified antimiR oligonucleotides were evaluated. With the addition of inhibitors 
to both let-7a and miR124a, this would cause de-repression of the specific targeted miRNA in the viral genome. 
Non-infected cells did not express any viral RNA copy number and hence, was not reflected in Fig. 3b. All RNA 
copy numbers were normalized and shown as fold differences of cells transfected with the scrambled anti-miR 
oligonucleotide control. Transfection of antimiR-124a and antimiR-let7a RNA oligonucleotides in SHSY-5Y cells 
dramatically knocked down endogenous miR-124a and let-7a expression and resulted in a significant increase in 
expression of RNA to 3.1-fold (Fig. 3b).
The RNA expression of the WT (2.7-fold) and the pIY-scr transfected RD cells (1.3-fold) were almost similar 
to cells transfected with scrambled anti-miR oligonucleotides (Fig. 3b). Similarly, the addition of the two scram-
bled inhibitors to SHSY-5Y cells produced almost similar RNA expression to that produced by the WT positive 
control and the pIY-scr transfected SHSY-5Y cells (1.2-fold). In the presence of inhibitors (anti-miR scr), there 
was no significant difference (P > 0.001) between the RNA expression of the pIY strain and the WT (1.2-fold) 
when NTERA-2 cells were transfected (Fig. 3b).
Quantitation of viral infectivity by tissue culture infectious dose (TCID50/ml). Table 1 shows the 
TCID50/ml values obtained from the effects of the pIY vaccine strain in different cell lines. The pIY miRNA 
vaccine strain in RD cells registered a significant (P = 0.0239) 4-log increase of log10 TCID50/ml (7.0 ± 0.5), 
when compared to the WT EV-A71 control (2.7 ± 0.8 log10 TCID50/ml). This observation is expected as the RD 
cells expressed cognate let-7a (Fig. 4). The miRNA vaccine strain (pIY)-infected SHSY-5Y cells displayed 5-log 
increase of 6.7 ± 0.5 log10 TCID50/ml, in comparison to the WT EV-A71 strain (0.5 ± 0.4 log10) (P = 0.0015). 
This could be explained by the presence of both let-7a or miR-124a in SHSY-5Y cells. This indicated that the pIY 
vaccine strain would need a significantly higher amount of virus to elicit a cytopathic effect (CPE) in 50% of the 
of the infected SHSY-5Y cells.
Figure 2. Quantification of viral titer (PFU/ml) in different cell lines. (a) The plaque assays were performed 
in monolayer cells. PFU/ml caused by (i) pIY-infected RD cells (ii) WT EV-A71 strain 41 in RD cells (iii) pIY-
scr-infected RD cells (iv) pIY-infected SHSY-5Y cells (v) WT EV-A71 strain 41 in SHSY-5Y cells (vi) pIY-scr-
infected SHSY-5Y cells (vii) pIY-infected NTERA-2 cells (viii) WT EV-A71 strain 41 in NTERA-2 cells (ix) pIY-
scr-infected NTERA-2 cells. (b) PFU/ml of the pIY vaccine strain, WT EV-A71 strain 41 and pIY-scr strain in 
three different cell lines. PFU/ml are the average of three biological replicates. Error bars indicate the standard 
deviation of the mean; P-values between the different groups with the one-way ANOVA. *P < 0.05, **P < 0.01.
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In addition, the pIY strain in NTERA-2 cells (2.3 ± 0.6 log10 TCID50/ml) showed no significant difference 
(P = 0.7444) to the WT strain 41 which expressed 1.7 ± 0.5 log10 TCID50/ml and the pIY-scr strain in NTERA-2 
cells (2.0 ± 0.6 log10 TCID50/ml). This observation could be explained by the lack of both miRNAs, let-7a and 
miR-124a, in NTERA-2 cells. Hence, there was no inhibition of EV-A71 mRNA translation in NTERA-2 cells. The 
pIY-infected SHSY-5Y and RD cells required 5-log increase of viruses to elicit CPE in 50% of the cells, when com-
pared with the pIY-scr strain in SHSY-5Y which expressed 0.7 ± 0.2 log10 TCID50/ml (P = 0.0058) and 2.7 ± 0.6 
log10 in RD cells (P = 0.0280), respectively. The TCID50/ml of the pIY-scr viral strain in RD cells also displayed 
Figure 3. Quantitation of viral RNA copy number in RD, SHSY-5Y and NTERA-2 cells. (a) Growth kinetics 
study of the pIY vaccine strain in RD, SHSY-5Y and NTERA-2 cells. Statistical analysis was done across all 
infected groups using a Mann–Whitney U-test. (b) Inhibition of the expressions of endogenous let-7a and 
miR-124a using anti-miR oligonucleotides corresponding to the let-7a and miR124a complementary sequence. 
Normalized RNA copy numbers are shown as fold differences of the scrambled anti-miR oligonucleotide 
control. Different cell lines were transfected with 25 pmol of anti-miR for let-7a and miR-124a and were then 
infected with pIY strain, pIY-scr and wild type EV-A71. The viral RNA copy numbers were quantified after 0, 
2, 4, 6, 8, 10, 12, and 24 h post-infection by Real-Time TaqMan RT-PCR and is the average of three biological 
replicates. Error bars indicate the standard deviation of mean; P-values between the varying groups with the 
one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.
Recombinant pIY vaccine strain in different 
cell lines TCID50/ml
pIY- infected RD cells 1.00 × 107
EV-A71 strain 41 in RD cells 5.60 × 102
pIY-scr-infected RD cells 4.47 × 102
pIY- infected SHSY-5Y cells 5.60 × 106
EV-A71 strain 41 in SHSY-5Y cells 0.30 × 10
pIY-scr-infected in SHSY-5Y cells 0.50 × 10
pIY-transfected NTERA-2 cells 1.85 × 102
EV-A71 strain 41 in NTERA-2 cells 5.61 × 10
pIY-scr-infected NTERA-2 cells 9.30 × 10
Table 1. Tissue culture infectious dose (TCID50/ml) of the recombinant pIY vaccine straina. aThe recombinant 
pIY vaccine strain carried 2 miRNA genes, as well as mutations in the 5′-NTR (∆11 bp) and G64R in the 3D 
polymerase.
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similar value (2.7 ± 0.8 log10 TCID50/ml) to the WT strain 41 (RD cells). The results indicated a high degree of 
attenuation of the pIY vaccine strain carrying the 2 miRNA target sequences in both SHSY-5Y and RD cells.
Genetic stability of the pIY miRNA vaccine strain in comparison to the MMS. Since both the 
multiply mutated strain, MMS and the pIY miRNA vaccine strains have shown significant reduction in virulence, 
it is necessary to assess the genetic stability of each of the mutations present in the viral genome by examining the 
potential of reversion of both types of mutants. This was performed by serial passaging and recovery of the viral 
strain after a series of 20 passages in RD cells. In the pIY miRNA vaccine strain, both miRNA target sequences 
viz. let-7a (AACTATACAACCTACTACCTCA) and miR-124a (TGGCATTCACCGCGTGCCTTA) were stable 
after 20 passages in RD cells. Studies performed to assess the genetic stability of the MMS showed that each of the 
6 single site mutations and the deletion mutation were stable in the MMS and did not revert to the WT genotype 
after 20 passages. The mutations that were stable in the MMS vaccine strain were present at the 5′-NTR (U700C), 
E145G at VP1–145, amino acid replacements at positions 98, 242, and 244 of VP1, G64R in the 3Dp°l and the par-
tial deletion (11 bp) in the 5′-NTR. The significant reduction in virulence of the virus carrying miRNAs let-7a and 
miR-124a target sequences in tissue culture cells have led us to further evaluate the effect of the miRNA vaccine 
strain on viral pathogenesis in 4-week old ICR mice.
Protective efficacy of the pIY miRNA vaccine strain in comparison to the MMS. Vaccination using 
the EV-A71 pIY miRNA and the MMS vaccine strains to prevent severe EV-A71 infection was investigated, whereby 
4-week old mice were challenged with 105 CCID50/ml of the mouse-adapted virus (MAV) strain that was originally 
isolated from a fatal EV-A71 human infection18. The inactivated vaccine (IV) strain is the EV-A71 WT sub-genotype 
B4 strain 41 which was subjected to heating at 56°C for 30 mins. This IV strain was tested for non-viability after 
infection of RD cells at a MOI of 0.1. As there was absence of cytopathic effect in the RD cells even after 48 h of incu-
bation, the IV was considered sufficiently inactivated and was ready to be used as a vaccine strain.
Protection experiments showed that mice inoculated with the pIY miRNA vaccine strain, MMS or IV strain 
inoculated by the intraperitoneal (i.p.) route were able to confer 100% protection from hind limb paralysis against 
the EV-A71 MAV challenge. All five mice from the PBS-inoculated group showed significant weight loss and hind 
limb paralysis on day 5-post infection. In contrast, the pIY miRNA vaccine strain, MMS and IV-inoculated mice 
showed no signs of weight loss but registered a steady increase in weight after EV-A71 MAV challenge (Fig. 5a). 
Mice that were inoculated with PBS reached an average health score of 4 at day 8 post-infection. This was based 
on the health score of clinical disease which was evaluated as follows: 0, healthy; 1, ruffled hair, hunchbacked (day 
4); 2, reduced mobility; 3, limb weakness (day 6); and 4, hind limb paralysis (days 8–10). These results showed 
that when the pIY miRNA vaccine strain and the MMS were administered by the i.p. route, they were able to 
confer 100% protection against hind limb paralysis following EV-A71 (MAV) challenge (Fig. 5b).
Production of Interferon-γ in response to stimulation by vaccine strains. Mice splenocytes were 
tested ex vivo against different vaccine strains for the production of IFN-γ by the ELISPOT assay. As the assay 
was performed ex vivo, this reflected the closest probable indicator of the human in vivo response. The splenocyte 
cells were stimulated for 24 h in the presence or absence of the pIY vaccine strain, the MMS or the IV. The MMS 
vaccine strain induced the highest IFN-γ response (765 SFU/106 T cells) ex vivo, followed by the pIY vaccine 
strain (640 SFU/106 T cells) and the IV (400 SFU/106 T cells) (Fig. 6a,b). Low levels of IFN-γ secretion was also 
detected in the negative control group that received PBS (50 SFU/106 T cells), albeit at a much significantly lower 
level (P < 0.001) than those elicited by the MMS and pIY vaccine strains. No response was detected in the wells 
containing media alone or media and cells which served as negative controls. Phytohemagglutinin-M (PHA-M) 
at 2.5 µg/ml and 5 µg/ml were tested to determine the optimal concentration for stimulation of IFN-γ in spleno-
cytes. The cellular response to 5 µg/ml PHA-M was strong with the samples and was a postive indicator that the 
ELISPOT assay was functioning at optimal levels.
Figure 4. Effects of pIY vaccine strain on TCID50/ml in different cell lines. The TCID50/ml values were 
calculated using the Reed and Muench formula determined from at least three independent experiments. Error 
bars indicate the standard deviation of mean; P-values between the varying groups with the one-way ANOVA. 
*P < 0.05, **P < 0.01, ***P < 0.001.
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Immunohistochemical staining of EV-A71 presence in organs of the vaccinated mice. The 
presence of the pIY vaccine strain, the MMS and the IV in mice was determined by immunohistochemical 
staining of the skeletal muscles and spinal cords harvested on day 10-post infection. For the PBS-inoculated 
group, the EV-A71 viral antigen was detected in the spinal cord and skeletal muscles of the hind limbs using 
immuno-histochemical analysis (Fig. 7a–c). In contrast, there was absence of viral antigen in at least 10 micro-
graphs of skeletal muscles of the hind limbs for the MMS (Fig. 7d), pIY (Fig. 7g) and IV-vaccinated groups of 
mice (Fig. 7i). In the 3 groups of vaccinated mice, there was no sign of inflammation or marked lesions in the 
tissue cryosections of the spinal cords (Fig. 7e, f and h). The results demonstrated the significance of the MMS, 
pIY vaccine strains and the IV in their capability to prevent systemic spread and EV-A71 replication in vivo.
Discussion
Enteroviruses such as EV-A71, CV-A6, CV-A8, CV-A10 and CV-A16 have led to over 7 million infections, 
including 2457 fatalities in China from 2008 to 2012. Five years of epidemiological surveillance in China (2008–
2014) showed that 43.73% of HFMD cases were due to EV-A7119. Some of these young children died of complica-
tions due to pulmonary edema, while others could not survive brain inflammations due to virulent genotypes of 
EV-A71. The lack of FDA-approved vaccines against EV-A71 highlights the urgency and significance of develop-
ing new vaccines against EV-A71 to prevent further fatalities. Pharmaceutical companies such as CAMS, Vigoo 
and Sinovac have obtained drug certificates and production licenses by China’s FDA for the inactivated vaccine 
(IV) against sub-genotype C4a20. Sinovac reported that the efficacy of their IV against EV-A71-associated hospi-
talization and HFMD cases with neurologic complications were both 100%21. Another study also showed an effi-
cacy rate of 95.1% against EV-A71-associated HFMD for the second year post-vaccination and an overall efficacy 
rate of 94.7% at two years22. It would be interesting to perform phase IV studies to assess the types of immune 
response and correlates of protection against all EV-A71 genotypes/sub-genotypes. Although the IV induces 
good humoral immunity, it requires multiple boosters and lacks strong cellular responses required for long-term 
protection. Therefore, there is a need to develop other types of vaccines which can induce robust humoral and 
cellular immunity.
The live attenuated vaccine (LAV) could serve as a safe and economical vaccine against HFMD as it can 
confer live-long immunity. Recent work has shown that it is possible to generate LAVs that have much lower 
risks of reversion. For example, attenuated high-fidelity mutants of EV-A71 with a single amino acid change, 
G64R in its 3D Polymerase (3DPol) was shown to significantly reduce viral virulence in vivo. The EV-A71 RG/
B4-G64R mutant had reduced virulence as it was unable to generate replication-efficient mutations and had 
markedly lower genetic diversity to withstand a range of selective pressures23. Hence, a high-fidelity EV-A71 
Figure 5. Protective efficacy conferred by vaccine strains in mice from lethal EV-A71 challenge. (a) Body 
weights were recorded for all 4-week old ICR mice after EV-A71 challenge until 10 days’ post-infection. Besides 
weight gain as an indicator of protective efficacy, other parameters such as alertness, activity and normal 
appetite were assessed. The results are expressed as the mean ± standard error of the mean of five mice. (b) 
Clinical scores of challenge with the EV-A71 MAV strain in 4-week old ICR mice inoculated with the pIY 
miRNA vaccine strain, MMS, and the IV. The control group was the mice administered with PBS but challenged 
with the mouse adapted virus (MAV) (n = 5).
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variant could increase genetic stability of the LAV. Previous success of using LAVs in the prevention of diseases 
such as poliovirus, yellow fever, rubella, measles, mumps, rabies, influenza and varicella zoster has proven that 
safe and effective LAVs could be developed through optimization of immunogenicity and genetic stability. One 
dose of oral administration of OPV could confer lifelong immunity. There are three attenuated strains, Sabin 1, 
2 and 3, being used as the OPV. However, the OPV was not safe enough as it was reported that the incidence of 
Vaccine-Associated Paralytic Poliomyelitis cases (VAPP) for immunocompetent children receiving their first dose 
of OPV was approximately 1 out of 750, 000 vacinees24. This could be due to too few mutations being present or 
they were genetically unstable. For example, Sabin 2 only carried 2 nt substitutions and this serotype was shown 
to cause significant reversion in the OPV recently25.
In this study, 2 microRNAs, viz. let-7a and miR-124a target genes, and the G64R (3Dpol) mutation was engi-
neered in the genome of the EV-A71 partial deletion mutant (∆11 bp in the 5′-NTR) to limit the degree of escape 
mutants. The let-7a and miR-124a target genes were incorporated into specific locations in the EV-A71 genome 
as these genetic regions were able to tolerate large insertions without any adverse effect on viral replication. The 
pIY vaccine strain carrying the miRNAs let-7a and miR-124a had decreased viral replication in both RD and 
SHYSY-5Y cells due to the presence of the corresponding cognate miRNAs in these two cell lines. The NTERA-2 
cells did not express either miR-124a or let-7a. This was observed in growth kinetics study that the pIY strain 
from infected NTERA-2 cells yielded significantly higher RNA copy number than the pIY strain from infected 
SHYSY-5Y or RD cells at every hour post-infection. The reduction in RNA copy number of the pIY strain in RD 
and SHSY-5Y cells were confirmed to be due to the presence of the miRNA target genes incorporated in the viral 
genome as the addition of inhibitors to both let-7a and miR124a caused a de-repression of the specific targeted 
miRNA in the viral genome.
The efficacy of the MMS and pIY vaccine strains to elicit immune responses against EV-A71 and ameliorate 
severe infection in mice when challenged with the MAV were evaluated in the present study. When either of the 
vaccine strains was administered, the MMS or the pIY vaccine strain was observed to be effective in inhibiting 
EV-A71 replication in the murine model. This demonstrated that both the MMS and the pIY vaccine strains 
were able to prevent the development of hind limb paralysis in mice receiving the MMS or the pIY vaccine strain 
via the i.p. route. Mice splenocytes were also tested ex vivo against different vaccine strains for IFN-γ response. 
Interestingly, both the pIY vaccine strain and IV did not elicit levels of IFN-γ as high as the MMS strain. This 
could be due to the presence of the ubiquitous let-7a in splenocyte cells which was able to bind to the let-7a com-
plementary sequence in the miRNA strain, hence reducing viral replication. This would in turn decrease the viral 
Figure 6. IFN-γ produced by mice inoculated with the pIY vaccine strain, the MMS and the IV. (a) The PBS-
inoculated mice (n = 5) served as the negative control group. PHA-M (2.5 µg/ml and 5 µg/ml) served as the 
positive controls for the IFN-γ assay. (b) Frequencies of cells producing IFN-γ in response to different vaccine 
strains measured using IFN-γ ELISPOT. The assays were carried out using vaccine-stimulated mice splenocytes 
incubated at 37 °C for 24 h. Data are expressed as SFU/106 T cells. ELISPOT positivity was defined as > 50 
SFU/106 T cells. Error bars represent median and interquartile range; P-values between groups with the one-way 
ANOVA. **P < 0.01, ****P < 0.0001.
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load but still retained a sufficient amount of immunogen needed to elicit a robust IFN-γ response. The expression 
of IFN-γ in particular, promotes cell-mediated immunity that is crucial for long-term memory and life-long 
protection from viral infections26.
As for the IV, the strain induced a poor T cell response as there is no viral multiplication in an IV and hence 
the reduced antigen levels could not sustain a prolonged antibody response. However, it has been reported that a 
formaldehyde-inactivated vaccine was able to protect 100% of immunized mice from weight loss, paralysis, and 
death. This could be due to the cross protective neutralizing antibodies (NtAbs) as the IV was able to neutralize 
sub-genotypes B3, B4 and C1 to C5, with the highest NtAbs against sub-genotypes B3 and B4 (≥ 1:512). The IV 
in this study was also able to neutralize sub-genotypes B3, B4 and C1 to C5 (1:32), but the lowest levels of NtAbs 
were against sub-genotypes B3 and B4 (1:16). The discrepancy could be attributed to different methods of pre-
paring the IV, using formaldehyde instead of heat-inactivation and different mice strains (ICR versus BALB/c) 
were used.
Notably, the MAV strain utilized for challenge by Ong et al. (2010) was similar to the one used to challenge 
the mice in this study27. The constraint of this MAV strain is that it is only effective in eliciting hind limb paralysis 
and death in mice that were 2 weeks old or younger. This limited the study design to only incorporate 1 booster 
vaccination and a time lapse of only 1 week between inoculations. The immaturity of the immune system of such 
young mice could result in lower levels of IFN-γ expression, than would have been elicited in older mice. Hence, it 
would be desirable for further studies to utilize a different challenge strain that could produce paralysis symptoms 
in older mice. This is important that the mice could be re-challenged with the MAV strain at a later stage to assess 
the long-term protective efficacy of the vaccine strains and to measure the expression levels of IFN-γ. It would be 
interesting to note any changes in the levels of IFN-γ as this cytokine is a vital component in the cellular immune 
response. The vaccination studies could be evaluated with both vaccine strains using IFN-γ−/− mice to assess if 
the protective efficacy obtained in this study was indeed due to the IFN-γ expression. It is notable that the MMS 
and pIY vaccine strains were able to induce elevated IFN-γ responses, similar to the virus-like particle (VLP) vac-
cine strain constructed by Zhao et al. (2015). The ChiEV-A71 VLPs were able to elicit high NtAb titers of ≥ 1:64 
and IFN-γ amounts of approximately 650 SFU/million splenocyte cells in immunized mice at 2-weeks after prime 
immunization. This was comparable to the levels of IFN-γ produced by the pIY vaccine strain at 670 SFU/million 
Figure 7. Tissue sections of mice vaccinated with pIY, MMS and IV in comparison with PBS inoculated group. 
The tissue sections were incubated with murine monoclonal antibody against EV-A71 VP1 as the primary 
antibody. Then the tissues were incubated with a peroxidase labelled polymer conjugated to goat anti-mouse 
IgG. Arrows indicate presence of viral antigen in the (a) spinal cord and (b,c) skeletal muscles of PBS-inoculated 
mice. Representative images indicating absence of EV-A71 viral antigen in the (d) skeletal muscles and (e) 
spinal cord of MMS-vaccinated mice, (f) spinal cord and (g) skeletal muscles of pIY-vaccinated mice, (h) spinal 
cord and (i) skeletal muscles of IV-vaccinated mice. Scale bars, 100 µM.
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cells. The IV produced by Zhao et al. (2015) induced higher IFN-γ at 580 SFU/million cells, compared to the lev-
els produced by the IV from this study at 380 SFU/million cells28. This could be due to the different age or breed 
of mice and different dosages of the vaccine strains (10 µg EV-A71 VLPs vs 104 PFU/ml vaccine).
The development of successful vaccines would require the production of strong and robust IFN-γ responses 
that play a vital role in the antiviral defense against EV-A71 infection. Mice deficient in IFN-γ receptors had 
higher fatality rates and more severe disease progression with EV-A71 infection. This was attributed to the role 
of viral proteins 2A and 3D that inhibited IFN regulatory factor 1 (IRF1) transactivation, prior to a loss of STAT1 
nuclear translocation. Blocking the 2A or 3D activity was able to restore IFN-γ signaling, whilst neuro-2a cells 
pre-treated with IFN-γ had decreased viral yield29. IFN-γ has been found to have antiviral functions and can 
decrease viral load in tissues of EV-A71 infected mice30,31. These activities are vital for viral clearance and might 
explain how the MMS, pIY vaccine strain and the IV were able to confer 100% protection against hind limb paral-
ysis in vaccinated mice. The vaccination would have induced the production of antigen presenting cells, natural 
killer cells, and T cells that elicited the antiviral IFN-γ which could effectively kill virus-infected cells.
High levels of IFN-γ have been shown to mediate viral clearance in lymphoid tissues and increase the sur-
vival rate of mice. AG129 mice lacking Type I and II Interferon receptors demonstrated progressive limb paralysis 
prior to death and histopathological examinations revealed a tremendous amount of damage in the brainstem and 
anterior horn areas32. In a separate study, a mouse adapted EV-A71 strain produced 100% lethality in 10-week old 
AG129 mice. The strain was only able to cause 17% lethality in A129 mice that lacked only Type 1 (α/β) Interferon 
receptors, indicative that adult AG129 mice are vulnerable to infection by MAV in the absence of a fully func-
tional IFN response33. In addition, Shen et al. (2013) discovered that infection with EV-A71 increased the levels 
of interferon-gamma-inducible protein-10 (IP-10), which in turn increased the expression of IFN-γ and the infil-
tration of CD8+ T cells to aid survival of mice34. This was similarly observed for the West Nile virus (WNV) as a 
lack of IFN-γ signaling demonstrated higher mortality to lethal infection with an increase in death from 30% (WT 
mice) to 90% in IFN-γ−/− or IFN-γR−/− mice. The protective role of IFN-γ against WNV was antiviral and this 
happened in peripheral lymphoid tissues, preventing its spread to the CNS35. It was shown that IFN-γ was critical 
for hepatitis viral clearance from the CNS oligodendroglia. Mice deficient in IFN-γ secretion (IFN-gamma0/0) 
demonstrated an inability to control viral replication through increased clinical symptoms and lethality linked 
with persistent virus36. It was also observed for dengue virus (DENV), presence of IFN-γ prevented systemic infec-
tion and paralysis in IFN-α/β receptor-deficient mice. In these doubly-deficient AG129 mice, IFN-γ restricted 
DENV replication in the spleen and bone marrow within 24 h of infection. This was attributed to a 140-fold greater 
resistance against systemic vascular leakage commonly associated with dengue infection37. Nevertheless, current 
knowledge of human cellular immunity towards EV-A71 remain limited. To date, only several studies have investi-
gated the role of cellular immunity against EV-A71 in small groups of human subjects based on in silico predicted 
peptides38,39. Hence, the role of T cells in EV-A71 protection remains to be explored.
In this study, both the MMS and pIY strain were able to elicit high IFN-γ levels (651–753 SFU/million spleno-
cytes) that may have conferred protection against hind limb paralysis in the 4-week old mice. A West Nile vaccine 
construct (WNVΔVax) designed by Brostoff et al.40 had increased safety and stability by similarly using miRNA 
targets with perfect complementarity for miR-124a and by incorporating multiple target sequences in cassettes 
with sufficient spacing for multiplicative silencing. In addition, viral replication was decreased in neuronal cells 
which expressed cognate miR-124a, as it was vital for the prevention of fatal brain encephalitis and meningitis. 
This attenuation provides an additional level of safety, and decreased the potential for selection of mutants in 
non-neuronal cells. At the same time, there was viral replication in peripheral cells (non-neuronal cells) to induce 
strong NtAb titers (PRNT90 ≥ 500–1700). Interestingly, all the detectable NtAb titers, regardless of magnitude, 
was found to be protective against challenge studies in CD-1 mice40.
As the pIY vaccine strain induced lower immunogenicity than the MMS and IV, this could be further 
increased by incorporating miR-155 into the strain. The insertion of miR-155 in the influenza A (H3N2) viral 
genome was found to increase immunogenicity in 8-week old mice. The C57.BL/6 mice vaccinated with the X31–
155 LAV elicited significantly higher levels of NtAb titres (1:256)41. A major concern with miRNA-based LAVs 
would be its genetic instability, and hence the possibility of escape mutants arising. Barnes et al.12 discovered that 
the recombinant poliovirus carrying miRNA let-7a did not replicate well in most tissues. This would then elicit 
a weaker immune response and served as a vaccine with low immunogenic properties. Although the poliovirus 
carrying the miR-124a (PV-124) could not replicate in neuronal tissues, it was able to grow extensively in other 
tissues. The virus was found to accumulate escape mutations that could prevent degradation of the viral genome. 
This also increases the potential for the PV-124 to revert to the WT genotype. In fact, several mice had low titers 
of mutated PV-124 virus in their spinal cords. Hence, to prevent viral escape from miRNA-mediated interference 
in replication, it is desirable to incorporate two different miRNA target sequences into the viral genome or by 
inserting the sequences in locations flanking regions of the 3′NTR that is efficient for viral replication.
To address any genetic stability or reversion to virulence, genetic stability studies of both the pIY miRNA 
strain and the MMS were evaluated in vitro. In the pIY vaccine strain, the 2 miRNA target genes, partial deletion 
(∆11 bp) and the G64R (3Dpol) mutations were stable and did not revert to WT even after 20 serial passages in 
RD cells. There was no single nucleotide substitution or loss of the miRNA target sequences after these passages. 
Since no escape mutants were observed for both miRNA targets, the miRNA vaccine strain of EV-A71 (pIY) is 
deemed to be genetically stable. In the MMS strain, each of the 6 single site mutations and the deletion mutation 
were stable and did not revert to the WT genotype after 20 passages. Future directions could look into in vivo 
serial passaging in mice to assess any potential of reversion to the WT. If there is no escape from miRNA targeting 
through point mutations, this further validates the safety of the strategy. Other neuronal-specific miRNA target 
genes such as miR-129, miR-154 or miR-433 could be incorporated into the miRNA-based EV-71 vaccine strain, 
in addition to miR-124a and let-7a as described in this study. Heterologous miRNAs could reduce selection pres-
sure as reported for miR-124a42.
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The absence of US FDA-approved vaccines for prevention of fatal HFMD caused by EV-A71 has intensified 
research into EV-A71 vaccine development. The IV is the lead vaccine candidate to enter the China market but 
it has only 80% efficacy against severe HFMD due to the poor development of the immune system in children. 
Therefore, there is a need to develop alternative vaccines such as the LAV that could induce long term cellular 
and humoral immune responses. Both the MMS and the miRNA-based pIY vaccine strains are promising vac-
cine candidates against severe HFMD as it conferred 100% protection against paralysis and elicited high levels 
of protective IFN-γ ex vivo. An absence of EV-A71 viral antigens in the skeletal muscles and spinal cords of mice 
vaccinated with both LAVs indicated the lack of infection in these sites. Hence, the MMS and the pIY vaccine 
strains are ready to be evaluated in larger animals such as the cynomolgus monkeys.
Materials and Methods
Ethics statement. All animal experimentations were performed in accordance with the Guidelines for 
Animal Experiments of the National Institute of Infectious Diseases (NIID, Tokyo, Japan). Experimental proce-
dures were reviewed and approved by the Institutional Animal Care and Use Committee, University of Malaya, 
Malaysia (IACUC Approval Number: 2016-191103/SUN/R/IYPT) and Sunway University Research Ethics 
Committee (IACUC Approval Number: SUREC 2016/010). Mice were housed in individually ventilated cages 
and provided with water and standard lab rodent diet. The mice were monitored daily for health and clinical 
signs. More than 20% body weight loss, hunching and ruffled fur were used as the criteria for euthanasia by CO2 
inhalation.
Cells and viruses. Human rhabdomyosarcoma (RD; ATCC #CCL-136), neuroblastoma (SH-SY5Y; ATCC 
#CRL-2266), African green monkey kidney cells (Vero; ATCC # CCL-81) and embryonal carcinoma cells 
(NTERA-2; ATCC # HTB-106) cells were maintained in DMEM (Invitrogen, USA) that was supplemented with 
10% FBS (Gibco, Calif., USA), 1% L-glutamine, 1% non-essential amino acids and 1% penicillin/streptomycin. A 
neuro-virulent EV-A71 strain 5865/SIN/00009 (Accession No.: AF316321; sub-genotype B4; designated as Strain 
41) was isolated from a deceased child during the Singapore HFMD outbreak in October 2000.
Insertion of miRNA target sequences into the EV-A71 genome. Specific primers were designed 
for the insertion of target sequences complementary to the two miRNAs (let-7a and miR124a) using 
Overlapping Extension PCR into two locations within the EV-A71 genome that contained the partial dele-
tion (∆11 bp) and G64R mutation (Table 2). Fragment 1 (768 bp) consisted of the 5′-NTR and let-7a target 
sequence (AACTATACAACCTACTACCTCA). Fragment 2 (2608 bp) comprised all the EV-A71 structural 
genes (VP1-VP4) flanked by the target sequences of let-7a and miR-124a (TGGCATTCACCGCGTGCCTTA). 
Fragment 3 (4099 bp) covered the entire non-structural genes (2A-2C and 3A-3D) alongside with the miR-124a 
target sequence.
Then, the three fragments (F1 + F2 and F3) were ligated using Overlapping Extension PCR. The PCR was per-
formed with the Phusion Hot Start II DNA Polymerase (2 U/µL) (Thermo Scientific, Calif., USA) and the 2-step 
cycling parameters which included an initial denaturation for 30 s at 98 °C, and 30 cycles of denaturation at 98 °C 
for 10 s, annealing at 72 °C for 30 s/kb, followed by a final extension at 72 °C for 10 minutes.
Cloning of EV-A71 carrying microRNA target sequences into the pCR-XL-TOPO vector. The  7.5 kb 
EV-A71 genome was cloned into the 3.5 kb pCR-XL-TOPO vector according to the manufacturer’s instructions 
(Invitrogen, Calif., USA). The recombinant pTOPO-miR7124 plasmid was subjected to DNA sequencing of the 
selected modified regions to confirm the presence of the microRNA target genes. The digestion and phenol chlo-
roform purification of the recombinant plasmid DNA was described previously43.
Reverse transcription of EV-A71 RNA into cDNA. The EV-A71 genomic RNA was reverse tran-
scribed into cDNA using SuperScript III First-Strand Synthesis System (Invitrogen, Calif., USA) according to the 
Primer Designation Nucleotide sequences
F1 (Fwd 5′-NTR) 5′-TTAAAACAGCTGTGGGTTGTACCCAC-3′
R1 (Rev let-7a) 5′-TGAGGTAGTAGGTTGTATAGTTGTTTGATTGTATTGAGG-3′
F2 (Fwd let 7a) 5′-AACTATACAACCTACTACCTCAATGGGCTCACAGGTGTC-3′
F2: (Fwd let 7a-scr) 5′-AATTACACGACTTATTATTTGAATGGGCTCACAGGTGTC-3′
R2: (let 7a-scr): 5′-TATGGGACCCGCTGTATCCCTAAGGGTAGTAATGGCAG-3′
R2 (Rev miR124a) 5′-TAAGGCACGCGGTGAATGCCAAAGGGTAGTAATGGCAG-3′
F3 (Fwd miR-124a) 5′-TGGCATTCACCGCGTGCCTTAGGAAAGTTCGGCCAGC-3′
F3 (Fwd miR-124a-scr) 5′-TAGCGTTAACTGCATGGCGCAGGAAAGTTCGGCCAGC- 3′
R3 (Rev 3′-NTR) 5′-GCTATTCCGGTTATAACAAATTTACCCCCACTAG-3′
Table 2. Nucleotide sequence of primers designed for the insertion of miRNA target sequences into EV-A71 
genome. Nucleotides that are in bold refer to the two miRNA target sequences. Primers designated let-7a-scr 
or miR124a-scr were primers designed to incorporate scrambled nucleotides into target sequences to produce 
virus controls that had disrupted base pairing with endogenous miRNA whilst conserving the WT encoded 
amino acids.
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manufacturer’s instructions. PCR amplification of the cDNA was performed with the DreamTaq DNA polymer-
ase (Thermo Scientific, Calif., USA) and the 3-step cycling parameters which included an initial denaturation for 
2 minutes at 98 °C, 25 cycles of denaturation at 98 °C for 10 s, 60 °C for 20 s and 72 °C for 4 minutes.
In vitro transcription of DNA into infectious RNA. RNA transcription from cDNA was carried out 
using RiboMAX™ Large Scale RNA Production System-SP6 (Promega, Calif., USA). The reaction was set up in 
20 µl of reaction volume following the manufacturer’s protocol. The reaction mixture was subjected to incubation 
at 37 °C for 4 h, followed by DNase treatment for 30 minutes. The DNase (Promega, Calif., USA) was added to 
the in vitro transcription reaction at a final concentration of 1 U per µg of DNA template. The in vitro transcribed 
EV-A71 RNA was visualized by agarose gel electrophoresis (90 V for 90 min) prior to its use in transfection of 
RD cells.
Transfection of infectious viral RNA. Overnight grown RD/SHSY-5Y/NTERA-2 cells (1.5 × 105 cells/
well in a 24-well plate) were prepared and used for transfection. In vitro transcribed viral RNA (1 μg) was trans-
fected into each well containing cells. The RNA in Opti-MEM was mixed with the Lipofectamine 2000 reagent 
(Invitrogen, Calif., USA) in Opti-MEM and incubated at room temperature for 20 minutes. Thereafter, the 
RNA-Lipofectamine mixture was added to the cells drop-by-drop. Four hours after transfection, the transfec-
tion medium was removed and replaced with 500 μL 10% FBS DMEM without penicillin/streptomycin (Gibco, 
Massachusetts, USA).
Addition of anti-miR inhibitors to different cell lines. Custom miRCURY LNA miRNA Power inhib-
itors and scrambled sequence inhibitors for let-7a and miR-124a were purchased from Qiagen (Calif., USA). The 
gene sequences for the anti-miR inhibitors for let-7a and miR-124a are AACUAUACAACCUACUACCUCA and 
UGGCAUUCACCGCGUGCCUUA, respectively. The scrambled gene sequences for the anti-miR inhibitors for 
let-7a and miR-124a are AAAUAGACCACAUAAUAACUAA and UGUCAUGCAACGAGUUCCGUA, respec-
tively. In both cases, 1.5 × 105 RD/SHSY-5Y/NTERA-2 cells were seeded in wells of a 24-well plate and transfected 
with 25 pmol anti-miR inhibitor specific for let-7a and 25 pmol anti-miR inhibitor specific for miR-124a with 
Lipofectamine 2000 reagent (Invitrogen, Calif., USA). After 24 h incubation, viral RNA transfection was carried 
out. Subsequently after 4 h, the transfection medium was removed and replaced with 500 μl 10% FBS DMEM 
without penicillin/streptomycin (Gibco, Massachusetts, USA).
Plaque assay. The amount of viral titer was quantified by the plaque assay as described previously16.
Tissue culture infectious dose (TCID50) assay. TCID50 is defined as the quantity of virus that will 
produce a cytopathic effect in 50% of the cultures inoculated. RD cells (3.0 × 104 cells/well) were seeded in a 
96-well plate a day before. On the next day, 10-fold serial dilutions of virus suspension were made using DMEM 
serum-free media as a diluent. This was carried out in quadruplicates in 96-well plates. The negative control 
wells contained uninfected RD cells. The plates were incubated at 37 °C and observed for CPE for up to 48 h. The 





TCID /ml (% wells infected at dilution next above 50%) (50%)
(% wells infected at dilution next above 50%) (% wells infected at dilution next below 50%)
dilution factor
50
RNA extraction from transfected cells. Viral RNA extraction was carried out from the supernatant of 
the transfected cells after 80% CPE was observed using the QIAamp® Viral RNA Mini Kit (Qiagen, Calif., USA) 
as previously described16.
Real time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). Real-time Reverse 
Transcriptase Polymerase Chain Reaction (RT-PCR) was carried out utilizing the TouchTM Real-Time Reverse 
Transcriptase PCR Detection System, CFX96 (Bio-Rad, Calif., USA). The real-time reverse transcriptase PCR was 
performed with the TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems, Calif., USA) utilizing the primers 
and the TaqMan probe designed for the quantitation of viral RNA copy number determination.
Genetic stability of the MMS and pIY vaccine strains. Genetic stability of the mutations in the MMS 
and the two miRNA target sequences in the pIY vaccine strain was examined during serial passages of the respec-
tive vaccine strains in RD cell cultures. RD cells were seeded with 500 μl of DMEM containing 5% FBS and 
3.0 × 105 cell per well in a 24-well plate. The growth medium was subsequently removed and 150 μl of supernatant 
containing each vaccine strain was added per well. The plate was incubated at 37 °C in a 5% CO2 incubator for 1 h. 
The plate was frozen and thawed three times and the contents of the well were centrifuged to remove cell debris. 
An aliquot of 150 μl of the cleared supernatant was used for the next passage of the MMS and pIY vaccine strains 
in triplicates for 20 passages. Stability of each of the mutations in the MMS or the miRNA target genes introduced 
into the miRNA vaccine strain was assessed through sequencing.
EV-A71 mice challenge studies. Groups of 2-week old mice (n = 5) were intraperitoneally (i.p.) immu-
nized with Freund’s complete adjuvant containing either 0.1 ml EV-A71 MMS (104 PFU/ml), pIY vaccine strain 
(104 PFU/ml) or the heat-inactivated (56 °C, 30 min) EV-A71 strain 41 (IV) (104 PFU/ml) using a 26 G needle. 
The control mice (n = 5) did not receive any inoculation of the vaccine strains, but was given 0.1 mL of PBS 
instead. After 1 week, mice were given the first booster dose of each vaccine strain (104 PFU/ml each) in Freund’s 
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incomplete adjuvant or PBS. After 14 days from the first immunization, all mice groups were challenged with 
the mouse adapted virus (MAV) by the i.p. route with 105 CCID50/ml. Clinical scores were defined as follows: 0, 
healthy; 1, ruffled hair, hunchbacked; 2, reduced mobility; 3, limb weakness; 4, hind limb paralysis; and 5, mori-
bund and death. At the end of the study (day 24), the mice were euthanized using CO2 asphyxiation. The skeletal 
muscles and spinal cords were subjected to immunohistochemistry analysis. The spleens were harvested for the 
Enzyme-Linked ImmunoSpot (ELISPOT) assay.
Preparation of murine splenocytes. The murine splenocytes were prepared according to a standard 
protocol44.
Mice ex vivo IFN-γ ELISPOT assay. Splenocyte cells were re-suspended to a concentration of 2.5 × 106/ml 
in complete RPMI and seeded at a density of 2.5 × 105 per well in a 96 well ELISPOT plate that contained immo-
bilized IFN-γ-specific monoclonal antibodies (mAb) from the IFN-γ ELISPOT kit (Mabtech, Ohio, USA). Wells 
that contained 5 µg/ml of purified phytohemagglutinin-M (PHA-M) (Sigma Aldrich, Calif., USA) served as pos-
itive control wells. The MMS and pIY vaccine strains or the IV, combined with Freund’s incomplete adjuvant 
were each added to the wells at a final concentration of 104 PFU/ml for overnight stimulation. After 24 h, the 
cells were removed and the detection mAb which was biotinylated was added. Thereafter, a streptavidin-enzyme 
conjugate was added and after addition of 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate, the number of spots 
were counted using the automated ELISPOT reader (Cellular Technology Limited, Ohio, USA) to determine the 
frequency of IFN-γ secreting cells.
Immunohistochemical analysis. On day 10-post infection, 20 sets of skeletal muscles and spinal cords 
of the ICR mice inoculated with either the MMS or pIY vaccine strains as well as the IV and PBS-injected mice 
were harvested and fixed in 10% buffered formalin for 1 week. Cryosections of 4 μm from the formalin-fixed 
tissues were made and mounted on Poly-L-lysine microscopic slides. Any endogenous peroxidase activity was 
quenched by incubating the tissue cryosections with an endogenous peroxidase blocking reagent for 20 min. The 
tissues were then incubated with murine monoclonal antibody against EV-A71 (Merck, New Jersey, USA). This 
was followed by incubation with a peroxidase labelled polymer conjugated to goat anti-mouse IgG for 30 min. A 
brownish-red colored peroxidase stain was developed using 3,3′-diaminobenzidine (DAB) substrate with a 5 min 
incubation and counterstained with hematoxylin (Sigma Aldrich, Calif., USA).
Statistical analysis. All the results were expressed as mean ± standard deviations (indicated by error bars in 
graph). Statistical analysis was performed by the two-tailed unpaired t-test or one-way ANOVA using GraphPad 
Prism 7.0 for Windows (GraphPad Software, Inc., San Diego, USA). All data not following a normal distribution 
were tested for statistical significance by a Mann–Whitney U-test; P values of less than 0.05 were considered as 
statistically significant.
Data Availability
The raw data required to reproduce these findings are available.
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